Abliva presents scientific data at international conference on mitochondrial medicine

AblivaPress release2023-06-12 08:30

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present scientific data from its KL1333 and NV354 programs at Euromit, an international conference in mitochondrial medicine, in Bologna, Italy, on June 11 – 15, 2023.

Euromit, the largest international meeting focused on mitochondrial medicine, brings mitochondrial disease researchers, physicians, clinical trial experts, and patient advocacy groups together every three years to discuss the latest advances in mitochondrial research and development. This year, the meeting is held in Bologna, Italy, starting on June 11.

The Abliva team will present experimental data from the company's two programs, KL1333 and NV354. The following research results will be presented:

Quinone compounds in primary mitochondrial disease: acute metabolic effects in human-derived cells in vitro.
Shilan Alsaied, Shusuke Sekine, Irene Yee, Imen Chamkha, Sonia Simón Serrano, Eleonor Åsander Frostner, Magnus J. Hansson, Eskil Elmér.
Quinone compounds in primary mitochondrial disease: in vitro characterization of NQO1-mediated NAD+/NADH modulation.
Imen Chamkha, Lee Webster, Steven J. Moss, Magnus J. Hansson, Eskil Elmér.
Succinate does not increase reactive oxygen species generation in phosphorylating human mitochondria.
Irene Yee, Alina Lenzer, Shusuke Sekine, Tianshi Liu, Imen Chamkha, Eskil Elmér, Johannes Ehinger.

The meeting also provides an important venue to interact with the mitochondrial community, and the Abliva team is looking forward to meetings with study doctors and coordinators involved in the ongoing Phase 2 FALCON study, as well as with patient advocacy groups.

Additional information about Euromit can be found at the website for the event (https://euromit2023.eu).

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is in clinical trials. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).